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OBJECTIVES We sought to determine the prognostic importance of myocardial reperfusion after various
contemporary interventional strategies in patients with acute myocardial infarction (AMI).
BACKGROUND The frequency, correlates, and clinical implications of myocardial perfusion after primary
angioplasty in AMI have not been examined in a large-scale prospective study. Similarly,
whether glycoprotein (GP) IIb/IIIa inhibitors and/or stents improve myocardial perfusion
beyond balloon angioplasty has not been investigated.
METHODS Tissue-level perfusion assessed by the myocardial blush grade was evaluated in 1,301 patients with
AMI randomized to balloon angioplasty versus stenting, each with or without abciximab.
RESULTS Despite Thrombolysis In Myocardial Infarction flow grade 3 restoration in 96.1% of patients,
myocardial perfusion was normal in only 17.4% of patients, reduced in 33.9%, and absent in
48.7%. Myocardial perfusion status post-coronary intervention stratified patients into three
distinct risk categories, with 1-year mortality rates of 1.4% (normal blush), 4.1% (reduced blush),
and 6.2% (absent blush) (p  0.01). Among patients randomized to angioplasty, angioplasty 
abciximab, stenting, and stenting  abciximab, normal myocardial perfusion was restored in
17.7%, 17.0%, 17.5%, and 17.6%, respectively (p  0.95), which was associated with similar
1-year rates of mortality in patients randomized to stenting versus angioplasty (4.5% vs. 4.8%, p
 0.91) and abciximab versus no abciximab (4.3% vs. 5.0%, p  0.63).
CONCLUSIONS Restoration of normal tissue-level perfusion is a powerful determinate of survival after primary
PCI in AMI and is achieved in a minority of patients. Neither stents nor GP IIb/IIIa
inhibitors significantly enhance myocardial perfusion compared to balloon angioplasty alone,
underlying the similar long-term mortality with these different mechanical reperfusion
strategies. (J Am Coll Cardiol 2004;44:305–12) © 2004 by the American College of
Cardiology Foundationi
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mestoration of normal epicardial (Thrombolysis In Myocar-
ial Infarction [TIMI] flow grade 3) flow has been strongly
elated to survival following reperfusion therapy during
See page 313
volving acute myocardial infarction (AMI) (1–4). Despite
IMI flow grade 3, however, echocardiographic and other
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yocardial perfusion, a finding that may result in persistent
T-segment elevation and diminished survival (5–18).
The myocardial blush grade (MBG) is an angiographic
urrogate of myocardial perfusion (9) and has been studied in
everal small- to moderate-sized single-center retrospective
eries of patients undergoing primary percutaneous coronary
ntervention (PCI) (9,11,12,15,16). The prognostic utility of
estored myocardial perfusion has not, however, been exam-
ned or confirmed in a large-scale multicenter prospective
tudy. Moreover, whether glycoprotein (GP) IIb/IIIa inhibi-
ors and/or stents improve myocardial perfusion beyond that
chieved by balloon angioplasty alone has not been investi-
ated. We therefore evaluated the frequency, correlates, and
linical implications of myocardial blush from an international
ulticenter prospective study of patients with AMI random-zed to contemporary mechanical reperfusion strategies: the
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Myocardial Perfusion After Primary Angioplasty July 21, 2004:305–12ontrolled Abciximab and Device Investigation to Lower Late
ngioplasty Complications (CADILLAC) trial.
ETHODS
atient population and trial design. The details of the
ADILLAC trial have been previously described (19). In
rief, 2,082 patients with AMI and symptom onset within
2 h onset due to native coronary artery occlusion were
andomized at 76 international centers in a 2  2 factorial
esign to primary balloon angioplasty  abciximab versus
rimary stenting  abciximab. Patients were enrolled with
T-segment elevation, new left bundle branch block, or
ther electrocardiographic abnormalities if angiography
emonstrated an occluded infarct vessel with associated
egional wall motion abnormality. The principal exclusion
riteria were cardiogenic shock, bleeding diatheses, renal
nsufficiency, and coronary anatomy not suitable for stent
lacement. Among patients randomized to angioplasty,
rossover to stenting (which occurred in 16% of patients)
as permitted for a residual stenosis of 50% or severe
issection. Crossover to abciximab (which occurred in 6.0%
f patients) was allowed for refractory slow or no reflow or
ersistent peri-stent thrombosis. Clinical follow-up contin-
ed for one year. Routine angiographic follow-up at seven
onths was prespecified in a subset of 900 eligible patients.
ngiographic analysis. Core laboratory analyses were per-
ormed as previously described by technicians blind to
linical outcomes (20). Antegrade blood flow in the infarct
essel was evaluated using the TIMI scale (21). Left
entricular ejection fraction (LVEF) was calculated by the
rea-length method (22) and regional wall motion was
etermined by the centerline chord method (23).
Myocardial blush was not prespecified during the initial
nalysis, as this concept originated after the CADILLAC
rotocol was formalized. Therefore, after the initial angio-
raphic analysis and return of the films to their original
nstitutions, a voluntary recall of all 2,082 films was performed
o evaluate myocardial perfusion at the angiographic core
aboratory of the Cardiovascular Research Foundation. All
ngiograms were analyzed by a single observer (C.O.C.) and
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications
GP  glycoprotein
LAD  left anterior descending artery
LVEF  left ventricular ejection fraction
MBG  myocardial blush grade
PCI  percutaneous coronary intervention
RCA  right coronary artery
TIMI  Thrombolysis In Myocardial Infarctionver-read for accuracy by a second physician (A.J.L. or.W.S.) blind to clinical outcomes. The methodology for
yocardial blush analysis used (derived from the original
wolle description) (9) has been previously described and
hown to have high intra- and interobserver reproducibility for
rior technicians (11), and for the current reviewers (C kappa
0.87 and 0.82 for intra- and interobserver variability,
espectively). A total of 1,301 angiograms fulfilled all three of
he following parameters and were considered technically
dequate for blush analysis: 1) at least one view was present
hat isolated the myocardial infarct zone; 2) angiographic runs
f sufficient duration were present to assess tissue-level perfu-
ion (usually requiring complete filling of the coronary venous
ystem); and 3) complete arterial opacification with backflow of
ontrast into the aorta was present, indicating adequate con-
rast filling of the epicardial coronary artery without occlusive
atheter wedging.
Myocardial blush was graded in the distribution of the
nfarct artery as previously described (9,11), based on the
aximal densitometric degree of contrast opacification:
BG-0/1 no or minimal myocardial contrast opacification;
BG-2  moderate contrast opacification but less than in
ither an ipsilateral or contralateral non-infarct artery; and
BG-3, normal myocardial blush or contrast opacification,
omparable with the other coronary arteries. When myocardial
lush persisted (“staining”), MBG-0 was assigned.
ata management and statistical analysis. Study moni-
ors verified 100% of case report form data, and all primary
nd point events were adjudicated by an independent
ommittee blind to randomization. The primary end point
as a composite of death, reinfarction, ischemic-driven
arget vessel revascularization, or disabling stroke.
Categorical data were compared using the Fisher exact
est for pairwise comparisons and the chi-square test for
hree-way comparisons. Continuous variables are presented
s median with interquartile ranges and were compared by
he Kruskal-Wallis test. Time-to-event data are summa-
ized and displayed as Kaplan-Meier estimates and com-
ared with the log-rank test. Stepwise logistic regression
nalysis selecting baseline variables with an entry/stay cri-
erion of p  0.10 was employed to determine the inde-
endent predictors of normal myocardial blush post-PCI.
ox proportional hazards regression was used to identify
ndependent correlates of one-year mortality. Variables
ntered into the model included age (as a continuous
ariable), gender, body mass index (as a continuous vari-
ble), diabetes, hypertension, prior AMI or bypass surgery,
illip class, infarct-artery, triple-vessel disease, time to
eperfusion (as a continuous variable), baseline and final
IMI flow grades, final MBG, stent implantation, and
bciximab use. As baseline left ventriculography was per-
ormed in only 79% of patients, LVEF was not included in
he main multivariate modeling. Left ventricular ejection
raction was, however, included in secondary multivariate
odels and the results were reported separately.
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July 21, 2004:305–12 Myocardial Perfusion After Primary AngioplastyESULTS
requency and correlates of myocardial blush after pri-
ary angioplasty. Of the 2,082 randomized patients, the
ndex angiograms from 1,500 patients (72%) were returned
or reanalysis. Compared with patients whose films were not
eturned for reanalysis, patients whose films were returned
ere slightly older and presented 18 min later; baseline
haracteristics, device randomization, and clinical outcomes
ere otherwise similar (Table 1). Of the 1,500 films
esubmitted for reanalysis, 1,301 (87%) were technically
uitable for MBG determination; these made up the current
tudy population.
At baseline, epicardial TIMI flow grade 3 was present in
1.8% of infarct vessels, whereas normal myocardial perfu-
ion (MBG-3) was seen in only 1.2% of patients (p 
.0001) (Fig. 1). Post-PCI, TIMI flow grade 3 was restored
n 96.1% of patients, compared with normal blush in only
Table 1. Baseline Features, Randomization, an
Film Reanalysis
R
(n
Age, yrs 6
Men
Diabetes
Symptom onset to balloon, h 4.08
Left anterior descending infarct artery
Triple-vessel disease
Left ventricular ejection fraction, % 56.6
TIMI flow grade 3, pre
Randomization
Angioplasty
Angioplasty  abciximab
Stenting
Stenting  abciximab
1-year outcomes
Mortality
Major adverse cardiac events
TIMI  Thrombolysis In Myocardial Infarction.
igure 1. Baseline and final Thrombolysis In Myocardial Infarction (TIM
ars  grade 0/1; hatched bars  grade 2; white bars  grade 3. PCI  perc7.4% of patients (p  0.0001) (Fig. 1). TIMI flow grade 3
as present in 100% of patients with normal (MBG-3)
yocardial perfusion, in 99.3% with reduced (MBG-2)
erfusion, and in 92.7% of patients with absent (MBG-0/1)
erfusion (p  0.0001).
As seen in Table 2, normal myocardial blush post-PCI was
chieved slightly more frequently in women and current
mokers, and when the infarct vessel was the right coronary
rtery (RCA). In contrast, absent myocardial blush post-PCI
as more common in diabetics, when the infarct artery was the
eft anterior descending artery (LAD), with lower baseline
VEF, and when pre-PCI TIMI flow grade 3 was not present.
inal MBG-3 condition was achieved in 6.1%, 13.2%, and
7.6% of patients when the infarct vessel was the LAD, left
ircumflex artery, and RCA, respectively (p  0.0001). Final
BG was unrelated to procedural parameters such as implan-
ation pressure, balloon size, or final luminal dimensions
chieved (Table 3). Final MBG-3 condition was achieved in
tcomes of Patients With and Without
lysis
,301)
No Reanalysis
(n  781) p
69) 58 (50–67) 0.01
% 74.9% 0.13
% 14.6% 0.55
7–6.50) 3.78 (2.78–5.72) 0.005
% 39.5% 0.06
% 15.1% 0.66
8–64.1) 55.2 (46.0–62.0) 0.003
% 22.5% 0.72
% 24.3% 0.65
% 26.2% 0.47
% 24.6% 0.99
% 24.9% 0.79
% 3.5% 0.24
% 16.1% 0.20
rates (left) and myocardial blush grades (right) in 1,301 patients. Blackd Ou
eana
 1
0 (51–
71.9
17.8
(2.9
35.5
15.8
(47.
21.8
25.2
24.8
24.6
25.4
4.7
18.5I) flow
utaneous coronary intervention.
1
b
v
i
M
7
I
a
c
g
b
p
w
4
m
P
o
t
u
a
i
v
m
[
e
i
h
T
C
A
M
T
S
A
M
M
R
M
D
T
A
308 Costantini et al. JACC Vol. 44, No. 2, 2004
Myocardial Perfusion After Primary Angioplasty July 21, 2004:305–129.9%, 17.3%, and 15.1% of patients with symptom onset to
alloon times of 3 h, 3 h, 6 h, and 6 h (chi-square p
alue for trend  0.26). By multivariate analysis, LAD
nfarct-related artery was the only independent predictor of
BG3 (hazard ratio 5.0 [95% confidence interval 3.2 to
.7], p  0.001).
mplications of myocardial perfusion status after primary
ngioplasty. Mortality at both 30 days and 1 year strongly
orrelated with final MBG (Table 4, Fig. 2). Survival was
reatest with normal blush, intermediate with reduced
lush, and least with absent blush. Among the 96.1% of
atients in whom TIMI flow grade 3 was restored, MBG
as normal in 18.1%, reduced in 35.1%, and absent in
6.8%. As seen in Figure 2, normal, reduced, and absent
able 2. Baseline Features Stratified by Postprocedure Myocardia
MBG-0/1
(n  633)
linical characteristics
Age, yrs 60 (51–69)
Men 75.0%
Diabetes 20.5%
Hypertension 47.7%
Hyperlipidemia 39.2%
Current smoker 40.1%
Prior myocardial infarction 14.1%
Killip class 2 10.9%
Symptom onset to balloon, h 4.43 (3.08–6.98)
3 h 44.7%
3 to 6 h 47.0%
6 h 55.9%
ngiographic characteristics
Infarct artery
Right 31.0%
Left anterior descending 50.0%
Left circumflex 19.0%
Triple-vessel disease 15.6%
Left ventricular ejection fraction, % 55.0 (47.4–63.0)
Reference vessel diameter, mm 2.92 (2.57–3.30)
Minimal luminal diameter, mm 0.00 (0.00–0.67)
TIMI flow grade
0/1 72.7%
2 9.0%
3 18.3%
BG  myocardial blush grade; TIMI  Thrombolysis In Myocardial Infarction.
able 3. Procedural and Angiographic Outcomes Stratified by Po
MBG-0/1
(n  633)
tent(s) implanted 57.3%
bciximab administered 52.6%
aximum balloon diameter, mm 3.34 (3.00–3.50)
aximum balloon pressure, atm 12 (9–15)
eference vessel diameter, mm 2.91 (2.59–3.33)
inimal luminal diameter, mm 2.20 (1.92–2.53)
iameter stenosis, % 23 (16–31)
IMI flow grade
0/1 2.5%
2 4.7%
3 92.7%bbreviations as in Table 2.yocardial perfusion grades separated patients with post-
CI TIMI flow grade 3 into three distinct strata with
ne-year mortality rates of 1.4%, 3.9%, and 5.7%, respec-
ively (p  0.02). Myocardial blush grade was statistically
nrelated to subsequent rates of reinfarction, clinical or
ngiographic restenosis, and myocardial recovery, though
nfarct artery reocclusion tended to be increased with absent
ersus present blush (Table 4).
As shown in Figure 3, MBG 3 was an independent
ultivariate predictor of late mortality (hazard ratio  2.70
95% confidence interval 1.06 to 6.86], p  0.037). How-
ver, when index LVEF was included in the model (reduced
n size to 989 patients to account for missing values), the
azard ratio for MBG 3 as a predictor of mortality
sh Grade
MBG-2
(n  441)
MBG-3
(n  227) p
61 (51–68) 61 (51–69) 0.97
71.2% 64.3% 0.008
14.5% 16.7% 0.03
49.2% 46.7% 0.81
39.2% 37.9% 0.93
46.5% 49.8% 0.02
15.6% 11.0% 0.26
9.5% 9.3% 0.67
3.95 (2.88–5.78) 3.82 (2.83, 5.80) 0.002
35.4% 19.9% —
35.7% 17.3% —
29.0% 15.1% —
55.3% 74.0% 0.0001
25.9% 12.3% 0.0001
18.8% 13.7% 0.17
17.0% 14.1% 0.61
59.0 (51.1–65.0) 61.0 (52.0–68.0) 0.001
2.95 (2.63–3.31) 2.95 (2.65–3.34) 0.32
0.00 (0.00–0.74) 0.00 (0.00–0.72) 0.06
64.3% 64.3% 0.005
11.1% 9.3% 0.49
24.5% 26.4% 0.01
cedure Myocardial Blush Grade
MBG-2
(n  441)
MBG-3
(n  227) p
56.5% 54.2% 0.72
53.7% 49.8% 0.62
3.50 (3.00–3.50) 3.50 (3.00–3.50) 0.24
12 (9–16) 12 (8–14) 0.55
2.96 (2.64–3.35) 3.03 (2.74–3.37) 0.02
2.24 (1.92–2.58) 2.31 (2.04–2.60) 0.07
23 (17–31) 23 (18–31) 0.67
0% 0% 0.0002
0.7% 0% 0.0001
99.3% 100% 0.0001l Blustpro
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July 21, 2004:305–12 Myocardial Perfusion After Primary Angioplastyecreased from 2.70 to 1.55, which was no longer significant
p  0.42).
yocardial blush and mortality as a function of drug and
evice assignment. As seen in Figure 4, myocardial per-
usion status postintervention was similar in patients ran-
omized to balloon angioplasty (n  328), angioplasty 
bciximab (n  323), stenting alone (n  320), or stenting
abciximab (n  330). Final MBG was also independent
f the use of stents or abciximab by treatment-received
nalysis (Table 3). Mortality at one year occurred in similar
roportions of patients randomized to stenting versus an-
ioplasty (4.5% vs. 4.8%, p  0.91), and abciximab versus
o abciximab (4.3% vs. 5.0%, p  0.63).
ISCUSSION
he principal findings of this report, the largest analysis to
ate examining the implications of myocardial perfusion
tatus after reperfusion in AMI, are that: 1) despite achieve-
ent of TIMI flow grade 3 in 96% of patients after
rimary PCI, normalized myocardial perfusion, as assessed
y the MBG, was present in 20% of patients; 2) patients
ith AMI involving the LAD, and those with depressed
aseline left ventricular function, are particularly unlikely to
ave normal myocardial perfusion restored after primary
CI; 3) abnormal myocardial perfusion post-PCI is a
owerful correlate of early and late mortality, even in
able 4. Clinical and Angiographic Outcomes Stratified by Myoc
All Patients
MBG-0/1
(n  633)
0-day events
Death 3.5%
Reinfarction 1.1%
Ischemic target vessel revascularization 3.7%
Disabling stroke 0.2%
Composite major adverse cardiac events 7.3%
-year events
Death 6.2%
Reinfarction 2.6%
Ischemic target vessel revascularization 13.8%
Disabling stroke 0.3%
Composite major adverse cardiac events 19.0%
7-Month Angiographic Follow-Up Cohort
MBG-0/1
(n  197)
eference vessel diameter, mm 2.80 (2.47–3.1
inimal luminal diameter, mm 1.69 (1.16–2.0
iameter stenosis, % 38 (28–55)
inary restenosis 33.5%
nfarct artery reocclusion 11.1%
VEF, index, % 53.3 (44.8–62
VEF, 7 months, % 57.2 (49.3–65
VEF improvement from index to 7 months, % 1.7 (–5.0–10
Z RWM, index, SD/chord –1.40 (–1.72–0
Z RWM, 7 months, SD/chord –0.90 (–1.30–0
Z RWM improvement from index to 7 months,
SD/chord
0.43 (–0.05–0
p  0.07 for MBG-0/1 vs. 2/3.
IZ RWM  infarct zone regional wall motion, measured in standard deviations/atients with TIMI flow grade 3; and 4) normal myocardialerfusion is restored in a similar proportion of patients after
alloon angioplasty and stenting, with no incremental ben-
fit present from adjunctive GP IIb/IIIa inhibition, under-
ying the similar early and late mortality after mechanical
eperfusion with the four strategies evaluated in the CA-
ILLAC trial.
The data from this large, prospective multicenter con-
rolled trial confirm and validate previous retrospective and
ingle center reports demonstrating that a significant pro-
ortion of patients with normal epicardial coronary flow
fter primary PCI have diminished tissue-level perfusion in
he myocardial regions subtended by the infarct vessel. In
he present series of 1,301 patients, despite achievement of
IMI flow grade 3 in 96% of infarct vessels, normal
yocardial perfusion was restored in only 17.4% of patients,
ompared to 19% to 39% of patients in four earlier studies
sing a similar maximal contrast-based methodology to
core blush (9,11,12,16). Conversely, absent myocardial
erfusion was present in 48.7% of patients in the present
tudy, compared to 29% to 40% in earlier reports
9,11,12,16). Whether the slightly lower rates of effective
yocardial perfusion in the present study are due to patient
election or subtle differences in core lab methodology is
ncertain. Nonetheless, it is clear that the majority of
atients do not achieve normal tissue-level perfusion after
rimary PCI for AMI.
l Perfusion Status Postintervention
MBG-2
(n  441)
MBG-3
(n  227) p
1.4% 0.4% 0.006
0.9% 0.9% 0.93
3.0% 5.3% 0.32
0% 0% 0.59
4.5% 5.7% 0.18
4.1% 1.4% 0.01
3.0% 2.3% 0.84
14.4% 14.4% 0.95
0.7% 0% 0.38
19.3% 15.7% 0.51
MBG-2
(n  134)
MBG-3
(n  65) p
2.87 (2.57–3.26) 2.94 (2.55–3.21) 0.34
1.75 (1.24–2.21) 1.68 (1.19–2.25) 0.42
38 (27–52) 37 (27–55) 0.64
26.9% 32.3% 0.43
6.0% 6.2% 0.19*
58.2 (51.7–65.5) 59.1 (51.2–66.6) 0.0001
62.3 (52.3–70.8) 61.3 (54.4–70.8) 0.005
2.1 (–5.3–10.0) 1.8 (–2.7–9.2) 0.92
–1.24 (–1.57–0.74) –1.17 (–1.49–0.80) 0.0002
–0.72 (–1.27–0.28) –0.63 (–1.11–0.14) 0.15
0.35 (–0.07–0.79) 0.42 (–0.12–0.77) 0.89
LVEF  left ventricular ejection fraction; MBG  myocardial blush grade.ardia
9)
8)
.1)
.3)
.10)
.88)
.40)
.77)The infarct vessel was by far the most important deter-
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Myocardial Perfusion After Primary Angioplasty July 21, 2004:305–12inate of post-PCI myocardial perfusion status. By multi-
ariate analysis, normal blush was five times less likely to be
btained after primary PCI of the LAD, and was most often
resent after RCA intervention. Electrocardiographic ST-
egment resolution is also less likely after primary PCI in
nterior infarction (8,24). The likelihood of restoring nor-
al myocardial blush after primary PCI also directly corre-
ated with the baseline LVEF, which has not been consid-
igure 2. Cumulative survival according to final myocardial blush grade
MBG) in all patients (upper graph) and in those with post-procedure
hrombolysis In Myocardial Infarction (TIMI) flow grade 3 (lower
raph). PCI  percutaneous coronary intervention.
igure 3. Multivariate predictors of one-year mortality. CI  confidence
nterval; HR  hazard ratio; TIMI  Thrombolysis In Myocardialpnfarction.red in prior reports (9,11,12,16). Moreover, abnormal
lush post-PCI was no longer significantly predictive of late
ortality when baseline LVEF was added to the predictive
odel. Thus, although the mechanisms underlying reduced
eperfusion success in patients with anterior MI and abnor-
al systolic function are unknown, reduced index LVEF,
AD involvement, and post-PCI MBG 3 are important
ovariates; larger studies are required to determine the
egree to which abnormal blush contributes to mortality
ndependent from these other risk factors. Conversely, in
ddition to the amount of myocardium at risk, the inability
o restore normal microcirculatory blood flow after primary
CI may contribute to the poor prognosis of patients with
educed LVEF and anterior infarction.
Although survival is lowest in patients not achieving
IMI flow grade 3 after primary PCI (regardless of blush
core) (9,11), the MBG grade is capable of stratifying
atients with TIMI flow grade 3 into different long-term
isk categories. Some (12,15,16) but not all (11) prior
tudies have suggested that the post-PCI prognosis of
atients with MBG-3 and MBG-2 are similar, implying the
ritical distinction is the restoration of an “open” versus a
closed” microcirculation. In contrast, in the present larger
tudy, three distinct strata of risk were identified, with the
rognosis of patients with MBG-2 intermediate between
BG-3 and MBG-0/1. This is more than an academic
bservation. If the goal were merely to restore an open
icrocirculation, this criterion would have been met in 50%
o 70% of patients in prior studies (9,12,16). Conversely, the
urrent study suggests that as many as 83% of patients are
ot achieving optimal reperfusion after primary PCI. In-
eed, in the present study the prognosis of patients with
BG-2 flow was closer to that of patients with MBG-0/1
han MBG-3 flow. Even in patients achieving TIMI flow
rade 3, those with MBG-2 and MBG-0/1 flow had
ne-year rates of mortality threefold and fourfold higher,
espectively, than those in whom normal tissue-level perfu-
ion was restored. These data suggest that measures capable
f enhancing myocardial perfusion after mechanical reper-
usion therapy might improve survival in a significant
igure 4. Incidence of final myocardial blush grade by randomized
reatment strategy. Black bars balloon angioplasty; bars with horizontal
ines  angioplasty  abciximab; white bars  stent; bars with diagonal
ines  stent  abciximab.roportion of patients.
o
p
c
A
r
l
i
i
i
t
w
i
l
p
o
t
o
t
c
d
s
i
w
b
s
e
i
m
a
s
a
p
s
S
b
t
a
c
o
f
w
r
r
p
m
s
r
e
d
c
i
d
b
t
T
o
r
b
h
u
F
s
p
e
C
g
r
fi
f
p
fl
s
fi
p
c
r
i
r
r
p
e
s
a
w
d
R
C
F
R
311JACC Vol. 44, No. 2, 2004 Costantini et al.
July 21, 2004:305–12 Myocardial Perfusion After Primary AngioplastyIn this regard, the CADILLAC trial offered the unique
pportunity to assess the relative capability of four contem-
orary mechanical reperfusion strategies to optimize myo-
ardial perfusion and thereby potentially enhance survival in
MI. Whereas stent implantation undoubtedly reduces
estenosis and infarct-artery reocclusion compared to bal-
oon angioplasty (4,19), initial concerns arose regarding
ncreased rates of distal embolization after stenting, result-
ng in diminished microcirculatory perfusion and possibly
ncreased mortality (4,25). Conversely, GP IIb/IIIa inhibi-
ors may enhance myocardial perfusion when administered
ith thrombolysis (26), and improved tissue-level perfusion
n a single small primary PCI study (27). In the present
arge randomized trial, however, comparing balloon angio-
lasty  abciximab to stenting  abciximab, the restoration
f normal myocardial perfusion was nearly identical among
he four groups, a finding that underlies the observation that
ne-year mortality was independent of treatment strategy in
he current substudy as well as in the entire randomized
ohort (28). These data provide reassurance that stenting
oes not mechanistically or clinically impair (nor enhance)
urvival compared to balloon angioplasty. Moreover, abcix-
mab, when administered minutes before primary PCI,
ould not be expected to have an effect on mortality on the
asis of enhanced tissue-level perfusion.
Of note, post-PCI myocardial perfusion status had no
ignificant impact on global and regional myocardial recov-
ry at seven months, in contrast to an earlier smaller study
n which convalescent six-month ventricular function was
easured with echocardiography (12). These data confirm
nd extend the “open-artery hypothesis” previously re-
tricted to epicardial vessel patency (29): that the benefits of
n intact microcirculation after reperfusion therapy on
rolonging survival accrue independently of myocardial
alvage.
tudy limitations. First, as the concept of blush had not
een developed during the formulation of the CADILLAC
rial, the current analysis was not prespecified. However, the
ngiographic techniques prespecified for the original proto-
ol were similar to those required for blush analysis. As 72%
f films were returned for blush analysis, and the baseline
eatures and outcomes of patients with and without blush
ere roughly comparable, this analysis may be considered
epresentative of the entire population. Moreover, the cur-
ent study is the largest and only multicenter analysis of the
redictors and prognostic implications of blush after pri-
ary PCI using contemporary techniques, and the only
uch study using data collected from a carefully controlled,
andomized trial employing blinded core labs and clinical
vent adjudication committees. Second, the visually assessed
ensitometric evaluation of MBG is subjective, though the
urrent and prior studies have reported very good intra- and
nterobserver variability (9,11,15). A computerized video-
ensitometric technique using background subtraction for
lush determination has been validated, but requires sophis-
icated methodology and is not widely applicable (30).hird, the relative prognostic impact of MBG in relation to
ther markers of reperfusion success, such as ST-segment
esolution, was not directly addressed in this investigation,
ut deserves further study. In this regard, some prior trials
ave found independent and non-overlapping prognostic
tility of both MBG and ST-segment resolution (12,16).
inally, these data apply only to the study population;
pecifically, MBG may have greater prognostic utility in
atients with cardiogenic shock (11), a group that was
xcluded from the current study.
linical implications. Despite high rates of normal ante-
rade epicardial flow, adequate tissue-level perfusion is
estored in a minority of patients after primary PCI, a
nding that has prognostic utility in risk-stratifying patients
or subsequent mortality. In concert with earlier studies, the
resent investigation suggests that achievement of TIMI-3
ow, though still a necessary component, is no longer
ufficient to define an optimal result of primary PCI or
brinolytic therapy (17); restoration of normal tissue-level
erfusion is also required. The causes of reduced microcir-
ulatory perfusion after reperfusion therapy are multifacto-
ial and include distal thromboemboli, vasoconstriction,
nterstitial edema, capillary leak syndrome, and possibly
eperfusion injury, among others. Additional studies are
equired to determine whether modalities that acutely im-
rove myocardial reperfusion success rates are able to further
nhance survival after primary PCI. In this regard, small
tudies have shown promise for adjunctive thrombectomy
nd distal vascular protection devices (25), the proof of
hich awaits the completion of adequately powered ran-
omized trials.
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